New sequence specific reagents targeting CCR5 in primary hematopoietic cells

• 收藏
• 分享

专利权人:

Cellectis;Albert-Ludwigs-Universität Freiburg

发明人:

Cathomen, Toni,Cornu, Tatjana,Duchateau, Philippe,Mussolino, Claudio,Romito, Marianna,Gouble, Agnes

申请号：

AU2018251150

公开号：

AU2018251150A1

申请日:

2018.04.13

申请国别(地区):

AU

年份:

2019

代理人:

摘要：

The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/